<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Case Rep Pulmonol</journal-id><journal-id journal-id-type="iso-abbrev">Case Rep Pulmonol</journal-id><journal-id journal-id-type="publisher-id">CRIM.PULMONOLOGY</journal-id><journal-title-group><journal-title>Case Reports in Pulmonology</journal-title></journal-title-group><issn pub-type="ppub">2090-6846</issn><issn pub-type="epub">2090-6854</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22937427</article-id><article-id pub-id-type="pmc">3420636</article-id><article-id pub-id-type="doi">10.1155/2011/494328</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Methaemoglobinemia Induced by MDMA?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Verhaert</surname><given-names>L. L. W.</given-names></name><xref ref-type="aff" rid="I1">
</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="I1"> Catharina Hospital Eindhoven, The Netherlands</aff><author-notes><corresp id="cor1">*L. L. W. Verhaert: <email>aaslvt@cze.nl</email></corresp><fn fn-type="other"><p>Academic Editor: S. Kr&#x000fc;ger</p></fn></author-notes><pub-date pub-type="ppub"><year>2011</year></pub-date><pub-date pub-type="epub"><day>19</day><month>10</month><year>2011</year></pub-date><volume>2011</volume><elocation-id>494328</elocation-id><history><date date-type="received"><day>23</day><month>6</month><year>2011</year></date><date date-type="accepted"><day>17</day><month>8</month><year>2011</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2011 L. L. W. Verhaert.</copyright-statement><copyright-year>2011</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>
<italic>Case</italic>. A 45-year-old man with a blank medical history presented at the emergency room with dizziness and cyanosis. Physical examination showed cyanosis with a peripheral saturation (SpO<sub>2</sub>) of 85%, he did not respond to supplemental oxygen. Arterial blood gas analysis showed a striking chocolate brown colour. Based on these data, we determined the arterial methaemoglobin concentration. This was 32%. We gave 100% oxygen and observed the patient in a medium care unit. The next day, patient could be discharged in good condition. Further inquiry about exhibitions and extensive history revealed that the patient used MDMA (3,4- methylenedioxymethamphetamine, the active ingredient of ecstasy). <italic>Conclusion</italic>. Acquired methaemoglobinemia is a condition that occurs infrequently, but is potentially life threatening. Different nutrients, medications, and chemicals can induce methaemoglobinemia by oxidation of haemoglobin. The clinical presentation of a patient with methaemoglobinemia is due to the impossibility of O<sub>2</sub> binding and transport, resulting in tissue hypoxia. 
Important is to think about methaemoglobin in a patient who presents with cyanosis, a peripheral saturation of 85% that fails to respond properly to the administration of O<sub>2</sub>. Because methaemoglobin can be reduced physiologically, it is usually sufficient to remove the causative agent, to give O<sub>2</sub>, and to observe the patient. 
</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Methaemoglobinemia is a condition that occurs infrequently but is potentially life threatening. The aetiology may be congenital or acquired. Methaemoglobin is haemoglobin in which the iron molecule is oxidized. It loses the ability to bind O<sub>2</sub>, and the O<sub>2</sub> affinity for each other haeme is raised, making the O<sub>2</sub> dissociation curve shifts to the left which results in tissue hypoxia [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B6" ref-type="bibr">2</xref>].</p><p>Small amounts of methaemoglobin are produced physiologically, but the relative proportion of the total haemoglobin is kept constant to 1% of the total haemoglobin by physiological reduction (NADH-dependent methemoglobin reductase) [<xref rid="B5" ref-type="bibr">3</xref>].</p><p>The most frequent case reports of acquired methaemoglobinemia are caused by dapsone and local anaesthetics (lidocaine). We present a case of acquired methaemoglobinemia possibly induced by MDMA (3,4-methylenedioxymethamphetamine, the active ingredient of ecstasy).</p></sec><sec id="sec2"><title>2. Case</title><p>A 45-year-old man with a blank medical history presented at the emergency room with dizziness and cyanosis. The discoloration was noticed by a colleague of him. On admission, he was well oriented in time and place. Physical examination showed cyanosis with a peripheral saturation (SpO<sub>2</sub>) of 85%, he did not respond to supplemental oxygen. He had a blood pressure of 140/70 mmHg, a pulse rate of 120/min, a SpO<sub>2</sub> 87% with 15 litres of oxygen, and a temperature of 37.3&#x000b0;C. Arterial blood gas analysis showed a striking chocolate brown colour and a pH of 7.38, PO<sub>2</sub> of 200&#x02009;mmHg, PCO<sub>2</sub> of 44&#x02009;mmHg, and a HCO<sub>3</sub> of 25.1&#x02009;mmol/L. Chest X-Ray showed as a chance finding a mass on the right lung basis (this appeared to be a carcinoid after lobectomy later) (<xref ref-type="fig" rid="fig1">Figure 1</xref>). </p><p>Based on these data, we determined the arterial methaemoglobin concentration. This was 32%. We gave 100% oxygen and observed the patient in a medium care unit. After one hour, the methaemoglobin concentration dropped to 23%. Another half hour later, the concentration was 16%. The next day, patient could be discharged in good condition.</p><p>Further inquiry about exhibitions and extensive history revealed that the patient used MDMA (3,4-methylenedioxymethamphetamine, the active ingredient of ecstasy). He used this more often, and after taking it, a blue discoloration of the hands and lips occurred but without vertigo and shortness of breath. At that night, he had used a large amount. Toxicological screening in urine showed &#x0003e;2000 micrograms per litre of amphetamine.</p><p>He did not use any other drug. He did use paracetamol for headache in big amounts. He did not eat or use products that can cause methaemoglobin (<xref ref-type="table" rid="tab3">Table 3</xref>). Further investigations to congenital methaemoglobinemia were negative.</p></sec><sec id="sec3"><title>3. Conclusion</title><p>Acquired methaemoglobinemia is a condition that occurs infrequently, but is potentially life threatening. Different nutrients, medications, and chemicals can induce methaemoglobinemia by oxidation of haemoglobin. Most common causative agents are nitrates and nitrites, local anaesthetics, aniline and dapsone [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B3" ref-type="bibr">4</xref>, <xref rid="B8" ref-type="bibr">5</xref>], <xref ref-type="table" rid="tab3">Table 3</xref>.</p><p>The clinical, presentation of a patient with methaemoglobinemia is due to the impossibility of O<sub>2</sub> binding and transport, resulting in tissue hypoxia [<xref rid="B7" ref-type="bibr">6</xref>].</p><p>Concentrations between 10% and 20% usually indicate cyanosis. This is mainly due to the methaemoglobin pigment and less because of deoxygenated haemoglobin. From a concentration of more than 20%, symptoms of respiratory distress, dizziness, headache, and fatigue develop. Lethargy and stupor origin from a concentration of 50% and death may occur from 70% of methaemoglobin concentration [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">7</xref>], <xref ref-type="table" rid="tab1">Table 1</xref>. </p><p>The diagnosis is made difficult by the conventional pulse oximeter because it is unreliable in the presence of methaemoglobin. The saturation is calculated based on the ratio of light absorption at two wavelengths (660 and 940&#x02009;nm). In contrast to oxy- and deoxyhaemoglobin, methaemoglobin absorbs both wavelengths similar. Because of this, there is always a saturation of about 85% measured, independent of O<sub>2</sub> delivery. The arterial blood gas analysis suggests that the patient is well oxygenated because the PaO<sub>2</sub> is based on a standard O<sub>2</sub> dissociation curve. Often is given 100% oxygen with even high PaO<sub>2</sub> values measured. The PO<sub>2</sub> tells something about the delivery of oxygen from the lungs to blood, but in the case of methaemoglobin, this oxygen is not useful for tissue [<xref rid="B6" ref-type="bibr">2</xref>, <xref rid="B2" ref-type="bibr">7</xref>]. Striking is the chocolate brown colour of the blood gas. The colour remains brown despite exposure to oxygen because of the inability to bind O<sub>2</sub>.</p><p>Important is to think about methaemoglobin in a patient who presents with cyanosis, a peripheral saturation of 85% that fails to respond properly to the administration of O<sub>2</sub>. </p><p>For the treatment of acquired methaemoglobinemia, it is important to do a detailed history for medication use, diet, drinking water, and hobbies to discover the causative agent [<xref rid="B6" ref-type="bibr">2</xref>, <xref rid="B4" ref-type="bibr">8</xref>]. Because methaemoglobin can be reduced physiologically, it is usually sufficient to remove the causative agent, to give O<sub>2</sub>, and to observe the patient.</p><p>At concentrations above 30%, it is generally recommended to administer methylene blue (1 to 2&#x02009;mg/kg about 5 minutes, if necessary, repeat after 1 hour). Methylene blue acts as an exogenous electron acceptor for the NADPH methemoglobin reductase. Note that high doses of methylene blue may paradoxically induce methaemoglobinemia [<xref rid="B3" ref-type="bibr">4</xref>, <xref rid="B4" ref-type="bibr">8</xref>]. It is contraindicated in glucose-6-phosphate dehydrogenase deficiency as methylene blue induces acute haemolysis. An alternative in this case is vitamin C 300 to 1000&#x02009;mg per day orally.</p><p>At concentrations above 50%, it may be necessary to include patients in an intensive care for haemodialysis or plasmapheresis.</p><p>We believe that in this case report methaemoglobinemia was caused by MDMA (3,4-methylenedioxymethamphetamine, the active ingredient of ecstasy), given the high concentration of amphetamines in urine (&#x0003e;2000 micrograms per liter) at admission and the recurrent appearance of cyanosis after taking MDMA. In the literature, there is not any case report described so far. Biochemical acetaminophen may also cause methaemoglobinemia, but this is only in very large amounts described in animals [<xref rid="B9" ref-type="bibr">9</xref>].</p><p>Methaemoglobin concentration at baseline was 32%. Since the patient had minimal complaints, we have given extra O<sub>2</sub> and observed the patient in a medium care unit. We checked frequent arterial blood gases, <xref ref-type="table" rid="tab2">Table 2</xref>. The methaemoglobin concentration after one hour had dropped to 23% (<xref ref-type="fig" rid="fig2">Figure 2</xref>). For this reason, we have not given IV methylene blue. The Patient could be discharged the next day.</p><p>This case illustrates the importance of thinking on the possibility of methaemoglobin. Since methaemoglobinemia is potentially life threatening, it is very important to discover the causative agents to avoid future problems.</p></sec></body><back><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>AH</given-names></name><name><surname>Kulig</surname><given-names>KW</given-names></name><name><surname>Rumack</surname><given-names>BH</given-names></name></person-group><article-title>Drug- and chemical-induced methaemoglobinaemia: clinical features and management</article-title><source><italic>Medical Toxicology and Adverse Drug Experience</italic></source><year>1986</year><volume>1</volume><issue>4</issue><fpage>253</fpage><lpage>260</lpage></element-citation></ref><ref id="B6"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>RO</given-names></name><name><surname>Lewander</surname><given-names>WJ</given-names></name><name><surname>Woolf</surname><given-names>AD</given-names></name></person-group><article-title>Methemoglobinemia: etiology, pharmacology, and clinical management</article-title><source><italic>Annals of Emergency Medicine</italic></source><year>1999</year><volume>34</volume><issue>5</issue><fpage>646</fpage><lpage>656</lpage><pub-id pub-id-type="pmid">10533013</pub-id></element-citation></ref><ref id="B5"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camp</surname><given-names>NE</given-names></name></person-group><article-title>Methemoglobinemia</article-title><source><italic>Journal of Emergency Nursing</italic></source><year>2007</year><volume>33</volume><issue>2</issue><fpage>172</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">17379039</pub-id></element-citation></ref><ref id="B3"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coleman</surname><given-names>MD</given-names></name><name><surname>Coleman</surname><given-names>NA</given-names></name></person-group><article-title>Drug-induced methaemoglobinaemia treatment issues</article-title><source><italic>Drug Safety</italic></source><year>1996</year><volume>14</volume><issue>6</issue><fpage>394</fpage><lpage>405</lpage><pub-id pub-id-type="pmid">8828017</pub-id></element-citation></ref><ref id="B8"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffin</surname><given-names>JP</given-names></name></person-group><article-title>Methaemoglobinaemia</article-title><source><italic>Adverse Drug Reactions and Toxicological Reviews</italic></source><year>1997</year><volume>16</volume><issue>1</issue><fpage>45</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">9192056</pub-id></element-citation></ref><ref id="B7"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Percy</surname><given-names>MJ</given-names></name><name><surname>McFerran</surname><given-names>NV</given-names></name><name><surname>Lappin</surname><given-names>TRJ</given-names></name></person-group><article-title>Disorders of oxidised haemoglobin</article-title><source><italic>Blood Reviews</italic></source><year>2005</year><volume>19</volume><issue>2</issue><fpage>61</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">15603910</pub-id></element-citation></ref><ref id="B2"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bradberry</surname><given-names>SM</given-names></name></person-group><article-title>Occupational methaemoglobinaemia: mechanisms of production, features, diagnosis and management including the use of methylene blue</article-title><source><italic>Toxicological Reviews</italic></source><year>2003</year><volume>22</volume><issue>1</issue><fpage>13</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">14579544</pub-id></element-citation></ref><ref id="B4"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>TA</given-names></name><name><surname>Hawkins</surname><given-names>S</given-names></name></person-group><article-title>A PACU crisis: a case study on the development and management of methemoglobinemia</article-title><source><italic>Journal of Perianesthesia Nursing</italic></source><year>2004</year><volume>19</volume><issue>4</issue><fpage>242</fpage><lpage>253</lpage><pub-id pub-id-type="pmid">15293175</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Kawabata</surname><given-names>M</given-names></name><name><surname>Tanaka</surname><given-names>S</given-names></name><name><surname>Maehara</surname><given-names>M</given-names></name><name><surname>Mishima</surname><given-names>A</given-names></name><name><surname>Murase</surname><given-names>T</given-names></name></person-group><article-title>Methemoglobinemia induced by combined use of sodium nitrate and acetoaminophen</article-title><source><italic>Internal Medicine</italic></source><year>2000</year><volume>39</volume><issue>10</issue><fpage>p. 860</fpage></element-citation></ref></ref-list></back><floats-group><fig id="fig1" position="float"><label>Figure 1</label><caption><p>X-ray at admission.</p></caption><graphic xlink:href="CRIM.PULMONOLOGY2011-494328.001"/></fig><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Concentration methaemoglobin over the time.</p></caption><graphic xlink:href="CRIM.PULMONOLOGY2011-494328.002"/></fig><table-wrap id="tab1" position="float"><label>Table 1</label><caption><p>Symptoms of methaemoglobinemia.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Methaemoglobin concentration</th><th align="center" rowspan="1" colspan="1">% Total haemoglobin</th><th align="center" rowspan="1" colspan="1">Symptoms</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">&#x0003c;1.5 g/dl</td><td align="center" rowspan="1" colspan="1">&#x0003c;10</td><td align="center" rowspan="1" colspan="1">None</td></tr><tr><td align="left" rowspan="1" colspan="1">1.5&#x02013;3.0&#x02009;g/dl</td><td align="center" rowspan="1" colspan="1">10&#x02013;20</td><td align="center" rowspan="1" colspan="1">Cyanotic skin discoloration</td></tr><tr><td align="left" rowspan="1" colspan="1">3.0&#x02013;4.5&#x02009;g/dl</td><td align="center" rowspan="1" colspan="1">20&#x02013;30</td><td align="center" rowspan="1" colspan="1">Anxiety, ligh headedness, headache, and tachycardia</td></tr><tr><td align="left" rowspan="1" colspan="1">4.5&#x02013;7.5&#x02009;g-dl</td><td align="center" rowspan="1" colspan="1">30&#x02013;50</td><td align="center" rowspan="1" colspan="1">Fatigue, confusion, dizziness, tachypnea, and tachycardia</td></tr><tr><td align="left" rowspan="1" colspan="1">7.5&#x02013;10.5&#x02009;g/dl</td><td align="center" rowspan="1" colspan="1">50&#x02013;70</td><td align="center" rowspan="1" colspan="1">Coma, seizures, arrythmias, and acidosis</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;10.5&#x02009;g/dl</td><td align="center" rowspan="1" colspan="1">&#x0003e;70</td><td align="center" rowspan="1" colspan="1">Death</td></tr></tbody></table></table-wrap><table-wrap id="tab2" position="float"><label>Table 2</label><caption><p>Blood gas analysis over the time.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Time</th><th align="center" rowspan="1" colspan="1">0</th><th align="center" rowspan="1" colspan="1">10&#x02009;min later</th><th align="center" rowspan="1" colspan="1">1 hour later</th><th align="center" rowspan="1" colspan="1">1.5 hour later</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">O<sub>2</sub> delivery</td><td align="center" rowspan="1" colspan="1">12 L O<sub>2</sub>
</td><td align="center" rowspan="1" colspan="1">15L O<sub>2</sub>
</td><td align="center" rowspan="1" colspan="1">15L O<sub>2</sub>
</td><td align="center" rowspan="1" colspan="1">10L O<sub>2</sub>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Ph</td><td align="center" rowspan="1" colspan="1">7.38</td><td align="center" rowspan="1" colspan="1">7.39</td><td align="center" rowspan="1" colspan="1">7.39</td><td align="center" rowspan="1" colspan="1">7.41</td></tr><tr><td align="left" rowspan="1" colspan="1">PCO<sub>2</sub> (mmHg)</td><td align="center" rowspan="1" colspan="1">44</td><td align="center" rowspan="1" colspan="1">44</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">43</td></tr><tr><td align="left" rowspan="1" colspan="1">HCO<sub>3</sub> (mmol/L)</td><td align="center" rowspan="1" colspan="1">25.1</td><td align="center" rowspan="1" colspan="1">25.9</td><td align="center" rowspan="1" colspan="1">25.7</td><td align="center" rowspan="1" colspan="1">26.4</td></tr><tr><td align="left" rowspan="1" colspan="1">PO<sub>2</sub> (mmHg)</td><td align="center" rowspan="1" colspan="1">200</td><td align="center" rowspan="1" colspan="1">240</td><td align="center" rowspan="1" colspan="1">250</td><td align="center" rowspan="1" colspan="1">300</td></tr><tr><td align="left" rowspan="1" colspan="1">Saturation (%)</td><td align="center" rowspan="1" colspan="1">ntb</td><td align="center" rowspan="1" colspan="1">97</td><td align="center" rowspan="1" colspan="1">97</td><td align="center" rowspan="1" colspan="1">98</td></tr><tr><td align="left" rowspan="1" colspan="1">Carboxyhaemoglobin (%)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">0.20</td><td align="center" rowspan="1" colspan="1">&#x02212;0.10</td><td align="center" rowspan="1" colspan="1">&#x02212;0.10</td></tr><tr><td align="left" rowspan="1" colspan="1">Methaemoglobin (%)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">32</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">16</td></tr></tbody></table></table-wrap><table-wrap id="tab3" position="float"><label>Table 3</label><caption><p>Causative agents of methaemoglobinemia.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" rowspan="1" colspan="1">Acetanilide</td><td align="left" rowspan="1" colspan="1">Hydroxylamine</td><td align="left" rowspan="1" colspan="1">Nitroprusside</td></tr><tr><td align="left" rowspan="1" colspan="1">Alloxan</td><td align="left" rowspan="1" colspan="1">Lidocaine</td><td align="left" rowspan="1" colspan="1">Paraquat/diquat</td></tr><tr><td align="left" rowspan="1" colspan="1">Aniline</td><td align="left" rowspan="1" colspan="1">Menadione</td><td align="left" rowspan="1" colspan="1">Phenacetin</td></tr><tr><td align="left" rowspan="1" colspan="1">Antipyrine</td><td align="left" rowspan="1" colspan="1">Metoclopramide</td><td align="left" rowspan="1" colspan="1">Phenazopyridine</td></tr><tr><td align="left" rowspan="1" colspan="1">Arsine</td><td align="left" rowspan="1" colspan="1">Methylene blue</td><td align="left" rowspan="1" colspan="1">Phenol</td></tr><tr><td align="left" rowspan="1" colspan="1">Benzene derivatives</td><td align="left" rowspan="1" colspan="1">Naphthalene</td><td align="left" rowspan="1" colspan="1">Phenylhydrazine</td></tr><tr><td align="left" rowspan="1" colspan="1">Benzocaine</td><td align="left" rowspan="1" colspan="1">Nitrates</td><td align="left" rowspan="1" colspan="1">Phenytoin</td></tr><tr><td align="left" rowspan="1" colspan="1">Chlorates</td><td align="left" rowspan="1" colspan="1">Nitroalkanes</td><td align="left" rowspan="1" colspan="1">Prilocaine</td></tr><tr><td align="left" rowspan="1" colspan="1">Chlorobenzene</td><td align="left" rowspan="1" colspan="1">Nitrochlorobenzene</td><td align="left" rowspan="1" colspan="1">Primaquine</td></tr><tr><td align="left" rowspan="1" colspan="1">Chloroquine</td><td align="left" rowspan="1" colspan="1">Nitrofuran</td><td align="left" rowspan="1" colspan="1">Smoke inhalation</td></tr><tr><td align="left" rowspan="1" colspan="1">Dapsone</td><td align="left" rowspan="1" colspan="1">Nitroglycerin</td><td align="left" rowspan="1" colspan="1">Sulphonamide antibiotics</td></tr><tr><td align="left" rowspan="1" colspan="1">Dinitrophenol</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">Trinitrotoluene</td></tr><tr><td align="left" rowspan="1" colspan="1">Dinitrotoluene</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td></tr></tbody></table></table-wrap></floats-group></article>